ALX Oncology
ALXO
Market cap $78.5M

1.49 USD

-0.01

0.67%

Updated Oct 22, 10:48 AM EDT

1 day

-0.67%

5 days

-4.49%

1 month

-25.13%

3 months

-77.86%

6 months

-89.53%

Year to date

-89.76%

1 year

-78.53%

5 years

-95.03%

About: ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Employees: 81

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,740 funds

0

Analysts bullish %

of 5 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

75% more call options, than puts

Call options by funds: $3.33M | Put options by funds: $1.9M

33% more repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 27

15% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 26

4% more funds holding

Funds holding: 106 [Q1] → 110 (+4) [Q2]

1.21% more ownership

Funds ownership: 91.98% [Q1] → 93.19% (+1.21%) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q1] → 2 (+0) [Q2]

43% less capital invested

Capital invested by funds: $514M [Q1] → $293M (-$221M) [Q2]

See Fund Rankings

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$3

101%

upside

Avg. target

$12.40

732%

upside

High target

$25

1,578%

upside

5 analyst ratings

3 positive

60%

2 neutral

40%

0 negative

0%

UBS Colin Bristow 33% 1-year accuracy 5 / 15 met price target	168%upside $4	Buy Maintained	16 Aug 2024
HC Wainwright & Co. Swayampakula Ramakanth 22% 1-year accuracy 24 / 109 met price target	1,578%upside $25	Buy Reiterated	13 Aug 2024
Stifel Bradley Canino 45% 1-year accuracy 15 / 33 met price target	101%upside $3	Hold Reiterated	9 Aug 2024
Stifel Bradley Canino 45% 1-year accuracy 15 / 33 met price target	236%upside $5	Hold Maintained	1 Aug 2024
HC Wainwright & Co. Swayampakula Ramakanth 22% 1-year accuracy 24 / 109 met price target	1,578%upside $25	Buy Reiterated	1 Aug 2024

See Analyst Rankings

Financial journalist opinion

ALX Oncology's Evorpacept Gains Momentum With FDA Fast Track Designations

ALX Oncology's Evorpacept, a first-in-class CD47 inhibitor, shows promising results in cancer treatment with reduced side effects and a favorable safety profile. Evorpacept's combination with TRP demonstrated improved response rates and longer duration of response in HER2-positive gastric and GEJ cancer trials. The ASPEN-06 trial also showed favorable results, with a 40.3% ORR in HER2-positive gastric/GEJ cancer, higher than the control group's 26.6%.

ALX Oncology's Evorpacept Gains Momentum With FDA Fast Track Designations

ALX Oncology Appoints Alan Sandler, M.D., to Board of Directors

- Dr. Sandler brings more than 30 years of experience and leadership in oncology and drug development - - Jaume Pons, Ph.D., and Sophia Randolph, M.D.

ALX Oncology Appoints Alan Sandler, M.D., to Board of Directors

ALX Oncology Reports Topline Data From ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Improves Tumor Response in Patients With HER2-Positive Gastric Cancer

SOUTH SAN FRANCISCO, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced topline data from its Phase 2 ASPEN-06 clinical trial. The trial demonstrated clinically meaningful improvements in overall response rate and duration of response among patients with previously treated HER2-positive advanced gastric cancer (GC) or gastroesophageal junction (GEJ) cancer.

ALX Oncology Reports Topline Data From ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Improves Tumor Response in Patients With HER2-Positive Gastric Cancer

ALX Oncology to Host Investor Call and Webcast to Share Topline Data Results From ASPEN-06 Phase 2 Clinical Trial of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer

SOUTH SAN FRANCISCO, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, announced that the Company will host an investor conference call and webcast today at 4:30 PM EDT to share topline data results from the Phase 2 ASPEN-06 clinical trial evaluating evorpacept for the treatment of advanced HER2-positive gastric cancer.

ALX Oncology to Host Investor Call and Webcast to Share Topline Data Results From ASPEN-06 Phase 2 Clinical Trial of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer

ALX Oncology: Finally Reaching A Reasonable Buy-In Valuation

ALX Oncology valuation has dropped below $500 million, presenting new studies at venues like ASCO, reaching a point of inflection. Evorpacept is the main focus, showing promising activity signals in gastric cancer and urothelial carcinoma, with upcoming data updates and trials. Financially, ALXO has a reasonable cash pool to fund operations for the near term, with a runway of 5-6 quarters.

ALX Oncology: Finally Reaching A Reasonable Buy-In Valuation

Zacks Investment Research

Down -30.79% in 4 Weeks, Here's Why ALX Oncology Holdings (ALXO) Looks Ripe for a Turnaround

The heavy selling pressure might have exhausted for ALX Oncology Holdings (ALXO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Down -30.79% in 4 Weeks, Here's Why ALX Oncology Holdings (ALXO) Looks Ripe for a Turnaround

ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer

SOUTH SAN FRANCISCO, Calif., June 02, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today presented data from its Phase 1 ASPEN-07 clinical trial in a poster presentation (abstract #4575) at the 2024 American Society of Cancer Oncology (“ASCO”) Annual Meeting being held in Chicago from May 31-June 4, 2024. These findings represent the first evorpacept combination data with an ADC from ASPEN-07's ongoing, open-label, single-arm, clinical trial of evorpacept in combination with PADCEV (enfortumab vedotin or “EV”) in patients with locally advanced or metastatic urothelial cancer (“la/m UC”). Evorpacept is a CD47 blocker with an inactivated Fc effector domain that is designed to minimize associated toxicity.

ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer

ALX Oncology Announces Participation in the Jefferies Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced that management will participate in the Jefferies Global Healthcare Conference. Details are as follows:

ALX Oncology Announces Participation in the Jefferies Global Healthcare Conference

Zacks Investment Research

Wall Street Analysts Think ALX Oncology Holdings (ALXO) Could Surge 36.64%: Read This Before Placing a Bet

The mean of analysts' price targets for ALX Oncology Holdings (ALXO) points to a 36.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Think ALX Oncology Holdings (ALXO) Could Surge 36.64%: Read This Before Placing a Bet

ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update

SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.

ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update

See News Rankings

Charts implemented using Lightweight Charts™